: Up over 267% YTD after reporting positive clinical data for its RAS/MAPK pathway-driven cancer treatments.
: Up over 204% YTD following successful Phase 3 trials for its psoriasis therapy. best buy stocks
: Up 301% YTD as of April 2026. It is currently the top performer in the S&P 500, benefiting from soaring demand for NAND flash memory used in AI data centers. : Up over 267% YTD after reporting positive
: Up over 267% YTD after reporting positive clinical data for its RAS/MAPK pathway-driven cancer treatments.
: Up over 204% YTD following successful Phase 3 trials for its psoriasis therapy.
: Up 301% YTD as of April 2026. It is currently the top performer in the S&P 500, benefiting from soaring demand for NAND flash memory used in AI data centers.